Rzewuska Małgorzata, Kuczyński Wojciech, Luks Małgorzata
Samodzielnej Pracowni Farmakoterapii IPiN w Warszawie.
Psychiatr Pol. 2004 May-Jun;38(3):453-68.
6-month multicentre, observational, open study evaluated the efficacy and tolerability of the new generation antipsychotic drug amisulpride in patients with acute schizophrenia.
99 patients were included in the study, 72 (72%) completed the 6-month observation.
Marked improvement in CGI after 6 months of treatment was observed in 56 (56%) patients. Therapy with amisulpride reduced both positive (20% reduction of positive symptoms in the PANSS positive subscale in 78%) and negative symptoms (20% reduction of negative symptoms in the PANSS negative subscale in 77%).
Amisulpride was well tolerated, adverse events responsible for premature withdrawal from the study were observed only in 6% patients.
一项为期6个月的多中心、观察性、开放性研究评估了新一代抗精神病药物氨磺必利对急性精神分裂症患者的疗效和耐受性。
99例患者纳入研究，72例（72%）完成了6个月的观察。
56例（56%）患者在治疗6个月后临床总体印象量表（CGI）有显著改善。氨磺必利治疗使阳性症状（78%的患者阳性和阴性症状量表中阳性症状减少20%）和阴性症状（77%的患者阴性和阴性症状量表中阴性症状减少20%）均减轻。
氨磺必利耐受性良好，仅6%的患者出现导致提前退出研究的不良事件。
